Hypertension and proteinuria: a class-effect of antiangiogenic therapies

Area of Science:

• Oncology
• Nephrology
• Pharmacology

Background:

• Antiangiogenic therapy is a key cancer treatment for solid tumors.
• Renal toxicity, including proteinuria and hypertension, is a known side effect.
• Bevacizumab, a VEGF inhibitor, is often associated with these renal toxicities.

Purpose of the Study:

• To investigate the link between antiangiogenic therapy and renal toxicity.
• To determine if renal side effects are specific to certain drugs or a class effect.
• To raise awareness among clinicians regarding the 'class effect' of VEGF pathway inhibitors.

Main Methods:

• Literature review of antiangiogenic therapies and their renal toxicity profiles.
• Analysis of the pharmacological action of drugs targeting the VEGF pathway.
• Comparison of side effect profiles across different antiangiogenic agents.

Main Results:

• Renal toxicities (proteinuria, hypertension) are linked to the inhibition of the VEGF pathway.
• These side effects occur with various antiangiogenic drugs, including those targeting circulating VEGF and VEGF receptors.
• Bevacizumab is not solely responsible; other agents like sunitinib, sorafenib, and axitinib share this toxicity profile.

Conclusions:

• Renal toxicity is a class effect of antiangiogenic therapies inhibiting the VEGF pathway.
• Clinicians must monitor patients for these side effects regardless of the specific antiangiogenic drug used.
• Awareness of this 'class effect' is crucial for appropriate patient management in cancer treatment.